Answers are grounded in this paper and cite their sources.
Randomized trial investigates base-edited T cells for relapsed leukemia, indicating immunotherapy risks.
The interim results of this phase 1 study support further investigation of base-edited T cells for patients with relapsed leukemia and indicate the anticipated risks of immunotherapy-related complications. (Funded by the Medical Research Council and others; ISRCTN number, ISRCTN15323014.).
No takes yet. Share an insight, caveat, or question.
Chiesa et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: